Human papillomavirus vaccine introduction in low-income and middle-income countries: guidance on the use of cost-effectiveness models

 

This item appears in the following Collection(s)

This is an Open Access article distributed under the terms of the Creative Commons Attribution License Except where otherwise noted, this item's license is described as This is an Open Access article distributed under the terms of the Creative Commons Attribution License